Evidence map›Paper›PMID 41077777›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

The Prognostic Role of Frailty and Its Recognition With Simple FRAIL and Fried Frailty Questionnaires in Advanced Cancer Patients.

Pia Weinländer, Sara Hadzibegovic, Jan Porthun, Lucie Kretzler, Ruben Evertz, Alessia Lena, Laura-Carina Lück, Jonathan L Hella, Ursula Wilkenshoff, Andrea Stroux and 14 more

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
  4. Frailty in Cancer: Why Bother and Ways Forward.Journal of cachexia, sarcopenia and muscle · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Pia WeinländerCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Sara HadzibegovicCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Jan PorthunCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Lucie KretzlerCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Ruben EvertzDepartment of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Alessia LenaCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Laura-Carina LückCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Jonathan L HellaCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Ursula WilkenshoffCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Andrea StrouxInstitute of Biometry and Clinical Epidemiology, Charité Medical University Berlin, Berlin, Germany.
Kalliopi KeramidaCardiology Department, General Anti-Cancer Oncological Hospital, Agios Savvas, Athens, Greece.
Anne LetschCharité Comprehensive Cancer Center, Charité - University Medicine Berlin, Berlin, Germany.
Dominik Paul ModestDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Lars BullingerDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Ulrich KellerDepartment of Hematology, Oncology and Cancer Immunology, Charité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt University Berlin, Berlin, Germany.
Mahir KarakasGerman Centre for Cardiovascular Research, Partner Site HH/Kiel/HL, Hamburg, Germany.
Youssef S AbdelwahedCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Philipp AttanasioCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Ursula RauchCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Carsten SkurkCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Wolfram DoehnerGerman Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
Ulf LandmesserCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.
Stephan von HaehlingDepartment of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany.
Markus S AnkerCharité - University Medicine Berlin Corporate Member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany.ORCID 0000-0002-4406-8555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with advanced cancer frequently suffer from frailty associated with vulnerability and adverse outcomes. Our aim was to assess the prevalence of frailty and elucidate the utility of two commonly used frailty questionnaires in an advanced cancer population.

methodsThe Fried Frailty Phenotype (FFP) and Simple FRAIL Questionnaire (SFQ) were assessed in hospitalized patients with mostly advanced cancer. Patients were classified by both questionnaires as frail (3-5 points), pre-frail (1-2 points) and robust (0 points) and followed up for all-cause mortality. Utility was evaluated with correlation and survival analysis.

resultsFrom 11/2017 to 02/2020, 251 mostly advanced cancer patients (61 ± 13 years, 53% men, BMI 25.3 ± 4.8 kg/m

conclusionFrailty and pre-frailty as assessed by FFP and SFQ are commonly found in advanced stage cancer patients. Both questionnaires have a strong correlation and are associated with all-cause mortality in this population. Since the SFQ is easier and quicker to perform, it can be used remotely, and with untrained staff, it might facilitate earlier preventive measures and initiate further actions to mitigate its impact.

Indexed as

FrailtyNeoplasmsAgedFemaleGeriatric AssessmentHumansMaleMiddle AgedPrognosisProspective StudiesSurveys and QuestionnairescancerfrailtyFried Frailty PhenotypemortalitySimple FRAIL Questionnaire

Identifiers

PMID41077777
PMCPMC12515984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.